(Yicai Global) May 11 -- BGI Genomics's product has become the first Chinese Covid-19 detection kit to be included in the World Health Organization's emergency use list amid the global fight against the virus.
The WHO added BGI Europe's real-time fluorescent RT-PCR kit, which involves a throat swab or bronchoalveolar lavage, onto its list as the fifth global entrant to suggest more high-quality tests for WHO member states, the Shenzhen-based firm said in a statement yesterday. That means that the United Nations and other procurement agencies are more likely to distribute the product now.
The move confirms product quality, which should upgrade BGI's global competitiveness and help prevent Covid-19 around the world, the firm added.
BGI has been benefiting from the pandemic-fuelled demand for diagnostic tools. The gene sequencing company's net profit increased by 43 percent to CNY140 million (USD19.8 million) in the first quarter from a year ago, according to its earnings report published earlier. Its revenue widened by 36 percent to CNY791 million.
BGI's stock price [SHE: 300676] was unchanged at CNY103.53 (USD14.62) in the afternoon.
Editor: Emmi Laine